Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 25, Issue 4, 2010, Pages 1183-1191

  Liabeuf, Sophie ^a   Barreto, Daniela V ^a   Barreto, Fellype C ^a   Meert, Natalie ^b   Glorieux, Griet ^b   Schepers, Eva ^b   Temmar, Mohammed ^a   Choukroun, Gabriel ^a   Vanholder, Raymond ^b   Massy, Ziad A ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cardiovascular disease; Chronic kidney disease; Mortality; P cresylsulphate; Uraemic toxins

Indexed keywords

ANTIDIABETIC AGENT; FREE 4 CRESYLSULFATE; INSULIN; PARA CRESOL; SULFATE; SULFUR ACID DERIVATIVE; TOTAL 4 CRESYLSULFATE; UNCLASSIFIED DRUG;

AGED; ANEMIA; ARTERIAL STIFFNESS; ARTICLE; BLOOD LEVEL; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART DEATH; HUMAN; IN VIVO STUDY; INFLAMMATION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; SURVIVAL;

AGED; BIOLOGICAL MARKERS; CRESOLS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PREDICTIVE VALUE OF TESTS; SULFURIC ACID ESTERS; SURVIVAL RATE;

EID: 77950234472     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp592     Document Type: Article

References (34)

1. Levin A, Foley RN. Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis 2000; 36: S24-S30
2. Vanholder R, Massy Z, Argiles A, et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056
3. Sarnak MJ, Coronado BE, Greene T, et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002; 57: 327-335
4. Vanholder R, De Smet R. Pathophysiologic effects of uraemic retention solutes. J Am Soc Nephrol 1999; 10: 1815-1823
5. Vanholder R, De Smet R, Hsu C, et al. Uraemic toxicity: the middle molecule hypothesis revisited. Semin Nephrol 1994; 14: 205-218
6. Vanholder R, Glorieux G, Lameire N. Uraemic toxins and cardiovascular disease. Nephrol Dial Transplant 2003; 18: 463-466
7. Curtius HC, Mettler M, Ettlinger L. Study of the intestinal tyrosine metabolism using stable isotopes and gas chromatography-mass spectrometry. J Chromatogr 1976; 126: 569-580
8. Burchell B, Coughtrie MW. Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfa-tion. Environ Health Perspect 1997; 105: 739-747
9. Martinez AW, Recht NS, Hostetter TH, et al. Removal of p-cresol sul-fate by hemodialysis. J Am Soc Nephrol 2005; 16: 3430-3436
10. De Smet R, David F, Sandra P, et al. A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. Clin Chim Acta 1998; 278: 1-21
11. Vanholder R, De Smet R, Waterloos MA, et al. Mechanisms of urae-mic inhibition of phagocyte reactive species production: characterization of the role of p-cresol. Kidney Int 1995; 47: 510-517
12. Dou L, Cerini C, Brunet P, et al. P-cresol, a uraemic toxin, decreases endothelial cell response to inflammatory cytokines. Kidney Int 2002; 62: 1999-2009
13. De Smet R, Van Kaer J, Van Vlem B, et al. Toxicity of free p-cresol: a prospective and cross-sectional analysis. Clin Chem 2003; 49: 470-478
14. Meijers BK, Bammens B, De Moor B, et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008; 73: 1174-1180
15. Bammens B, Evenepoel P, Keuleers H, et al. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006; 69: 1081-1087
16. de Loor H, Bammens B, Evenepoel P, et al. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uraemic and normal serum. Clin Chem 2005; 51: 1535-1538
17. Schepers E, Meert N, Glorieux G, et al. P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007; 22: 592-596
18. Meijers BK, Van Kerckhoven S, Verbeke K, et al. The uraemic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 2009; 54: 891-901
19. Meert N, Eloot S, Waterloos MA, et al. Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrol Dial Transplant 2009; 24: 562-570
20. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008; 51: 395-406
21. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266
22. Zureik M, Temmar M, Adamopoulos C, et al. Carotid plaques, but not common carotid intima-media thickness, are independently associated with aortic stiffness. J Hypertens 2002; 20: 85-93
23. Asmar R, Benetos A, Topouchian J, et al. Assessment of arterial dis-tensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995; 26: 485-490
24. Kauppila LI, Polak JF, Cupples LA, et al. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis 1997; 132: 245-250
25. Fitzmaurice G. Confounding: propensity score adjustment. Nutrition 2006; 22: 1214-1216
26. Cerini C, Dou L, Anfosso F, et al. P-cresol, a uraemic retention solute, alters the endothelial barrier function in vitro. Thromb Haemost 2004; 92: 140-150
27. Dou L, Bertrand E, Cerini C, et al. The uraemic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004; 65: 442-451
28. Evenepoel P, Bammens B, Verbeke K, et al. Acarbose treatment lowers generation and serum concentrations of the protein-bound solute p-cresol: a pilot study. Kidney Int 2006; 70: 192-198
29. Schulman G, Agarwal R, Acharya M, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006; 47: 565-577
30. Niwa T, Ise M, Miyazaki T, et al. Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uraemic rats. Nephron 1993; 65: 82-87
31. Ueda H, Shibahara N, Takagi S, et al. AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Ther Apher Dial 2007; 11: 189-195
32. Ueda H, Shibahara N, Takagi S, et al. AST-120 treatment in pre-dial-ysis period affects the prognosis in patients on hemodialysis. Ren Fail 2008; 30: 856-860
33. Meijers BK, De Preter V, Verbeke K, et al. p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. 2009 Aug 19. [Epub ahead of print]
34. Manolio T. Novel risk markers and clinical practice. N Engl J Med 2003; 349: 1587-1589